In re Bard IVC Filters Products Liability Litigation

Judicial Panel on Multidistrict Litigation

In re Bard IVC Filters Products Liability Litigation

122 F. Supp. 3d 1375, 2015 U.S. Dist. LEXIS 107666, 2015 WL 4885543

CourtUnited States Judicial Panel on Multidistrict Litigation

DecidedAugust 17, 2015

DocketMDL No. 2641

StatusPublished

Cited by3 cases

This text of 122 F. Supp. 3d 1375 (In re Bard IVC Filters Products Liability Litigation) is published on Counsel Stack Legal Research, covering United States Judicial Panel on Multidistrict Litigation primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook

In re Bard IVC Filters Products Liability Litigation, 122 F. Supp. 3d 1375, 2015 U.S. Dist. LEXIS 107666, 2015 WL 4885543 (jpml 2015).

Pincite

Opinion

TRANSFER ORDER

MARJORIE O. RENDELL, Acting Chair.

Before the Panel

*: Plaintiff in an action in- the Eastern District of- Pennsylvania (Ebert) moves under 28 U.S.C. § 1407 to centralize pretrial proceedings in the Northern District of Texas or the District of Nevada. The litigation, consists of 22 actions listed on Schedule A.¹

Plaintiffs in fifteen actions and five potential tag-along actions support the motion and, plaintiffs in six of these actions alternatively suggest centralization in the Middle District of Florida. Defendants C.R. Bard, Inc. and Bard Peripheral Vascular, Inc. (BPV and together, Bard) oppose centralization or, alternatively, suggest centralization in the District of Arizona or the Middle District of Florida.

[1376]*1376After considering the argument of counsel, we find that the actions in this litigation involve common questions of fact, and that centralization in the District of Arizona will serve the convenience of the parties and witnesses and promote the just and efficient conduct of the litigation. All actions involve common factual questions arising from allegations that defects in the design of Bard’s retrievable inferior vena cava filters (“IVC filters”) make them more likely to fracture, migrate, tilt, or perforate the inferior vena cava, causing injury. Centralization will eliminate dupli-cative discovery, avoid inconsistent pretrial rulings (including with respect to discovery, privilege, and Daubert motion practice), and conserve the resources of the parties, their counsel and the judiciary.

In opposing centralization, Bard does not dispute that these actions share questions of fact or that discovery will overlap. Rather, Bard argues, inter alia, that (1) the common discovery left to be completed is individual in nature, (2) continued informal coordination among the limited number of counsel is a better solution than formal centralization, and (3) the status of these cases counsels against centralization. The parties dispute the status of discovery, with responding plaintiffs arguing, for example, that Bard has refused to produce updated discovery since its initial productions to previous plaintiffs, while Bard argues that plaintiffs have not sought additional discovery in two years. At oral argument, plaintiffs argued that they will seek to reopen discovery in all cases to seek information relating to a recent warning letter issued to Bard by the Food and Drug Administration (FDA), while Bard argued that the letter is largely irrelevant to the pending actions and that it will produce its communications with'the FDA. While acknowledging that there has been some duplication in pretrial motions practice, Bard argues that this is because plaintiffs insist on pressing the same privilege issue unsuccessfully in various courts. Centralization will streamline these discovery disputes, allow the parties to brief plaintiffs’ request for additional discovery once, and result in one ruling on the contested privilege issue. Even if plaintiffs’ counsel are successfully coordinating their discovery efforts and scheduling, re-litigation of the same issues in different courts significantly impacts the parties and the judiciary.

Several of the pending cases have completed discovery and some are near trial. Given the ongoing overlapping discovery disputes, we find that centralization still would promote efficiencies. While it may be that some cases are too advanced to substantially benefit from inclusion in centralized proceedings, the parties have not specifically identified any that should be excluded. The Panel has held that the transferee court is in the best position to identify claims that should be excluded from an MDL. See In re: Nat’l Football League Players’ Concussion Injury Litig., 842 F.Supp.2d 1378, 1379 (J.P.M.L.2012) (“[W]e are persuaded that the transferee judge is in the best position to determine whether those claims are sufficiently related to the NFL claims to remain in centralized proceedings. If the transferee-judge determines after close scrutiny that remand of any claims is appropriate, procedures are available whereby this may be accomplished with a minimum of delay.”).

We are persuaded that the District of Arizona is an appropriate transferee district for this litigation. Defendant BPV— the Bard entity responsible for the design, testing, marketing, labeling, and post-market surveillance of Bard’s IVC filters — is [1377]*1377headquartered in this district and, therefore, documents and witnesses will be found there. The District of Arizona is not burdened by many MDLs and has the capacity and resources to successfully guide this litigation. Judge David G. Campbell, who sits in this district, is an experienced transferee judge who can prudently steer the litigation. Though a related action is not currently pending in the District of Arizona, we have found that is not a bar to centralization in a particular district. See, e.g., In re: New Motor Vehicles Canadian Exp. Antitrust Litig., 269 F.Supp.2d 1372, 1373 (J.P.M.L.2003) (centralizing six actions in the District of Maine though no constituent action was pending in that district).

IT IS THEREFORE ORDERED that the actions listed on Schedule A are transferred to the District of Arizona, and, with the consent of that court, assigned to the Honorable David G. Campbell for coordinated or consolidated pretrial proceedings.

SCHEDULE A

MDL No. 2641 — IN RE: BARD IVC FILTERS PRODUCTS LIABILITY LITIGATION

Central District of California

SIZEMORE v. C.R. BARD, INC, ET AL., C.A. No. 2:15-01945

Middle District of Florida

TILLMAN v. C.R. BARD, INC, ET AL., C.A. No. 3:13-00222 WYATT v. C.R. BARD, INC., ET AL., C.A. No. 6:14-01853

OCASIO, ET AL. v. C.R. BARD, INC., ET AL., C.A. No. 8:13-01962

Middle District of Georgia

MILTON v. C.R. BARD, INC., ET AL., C.A. No. 5:14-00351

Northern District of Illinois

JACKSON, ET AL. v. C.R. BARD, INC, ET AL., C.A. No. 1:14-04080

Eastern District of Michigan

MCCLARTY, ET AL. v. C.R. BARD, INC, ET AL., C.A. No. 4:14-13627

Northern District of Mississippi

MUNSON v. C.R. BARD, INC, ET AL., C.A. No. 3:14-00279

Western District of Missouri

LEUS v. C.R. BARD, INC., ET AL., C.A. No. 4:13-00585

District of Nebraska

KRUSE v. C.R. BARD, INC., ET AL., C.A. No. 8:15-00108

District of New Mexico

ROWE v. C.R. BARD, INC., ET AL., C.A. No. 1:15-00173

Western District of New York

MERRITT v. C.R. BARD, INC., ET AL., C.A. No. 1:14-00917

Northern District of Ohio

ROEDER v. C.R. BARD, INC, C.A. No. 3:15-00858

Eastern District of Pennsylvania

WETZEL v. C.R. BARD, INC., ET AL., C.A. No. 2:14-02729

EBERT v. C.R. BARD, INC., ET AL., C.A. No. 5:12-01253

KEEN v. C.R.

Free access — add to your briefcase to read the full text and ask questions with AI

TRANSFER ORDER

MARJORIE O. RENDELL, Acting Chair.

Before the Panel
*: Plaintiff in an action in- the Eastern District of- Pennsylvania (Ebert) moves under 28 U.S.C. § 1407 to centralize pretrial proceedings in the Northern District of Texas or the District of Nevada. The litigation, consists of 22 actions listed on Schedule A.¹

Plaintiffs in fifteen actions and five potential tag-along actions support the motion and, plaintiffs in six of these actions alternatively suggest centralization in the Middle District of Florida. Defendants C.R. Bard, Inc. and Bard Peripheral Vascular, Inc. (BPV and together, Bard) oppose centralization or, alternatively, suggest centralization in the District of Arizona or the Middle District of Florida.

[1376]*1376After considering the argument of counsel, we find that the actions in this litigation involve common questions of fact, and that centralization in the District of Arizona will serve the convenience of the parties and witnesses and promote the just and efficient conduct of the litigation. All actions involve common factual questions arising from allegations that defects in the design of Bard’s retrievable inferior vena cava filters (“IVC filters”) make them more likely to fracture, migrate, tilt, or perforate the inferior vena cava, causing injury. Centralization will eliminate dupli-cative discovery, avoid inconsistent pretrial rulings (including with respect to discovery, privilege, and Daubert motion practice), and conserve the resources of the parties, their counsel and the judiciary.

In opposing centralization, Bard does not dispute that these actions share questions of fact or that discovery will overlap. Rather, Bard argues, inter alia, that (1) the common discovery left to be completed is individual in nature, (2) continued informal coordination among the limited number of counsel is a better solution than formal centralization, and (3) the status of these cases counsels against centralization. The parties dispute the status of discovery, with responding plaintiffs arguing, for example, that Bard has refused to produce updated discovery since its initial productions to previous plaintiffs, while Bard argues that plaintiffs have not sought additional discovery in two years. At oral argument, plaintiffs argued that they will seek to reopen discovery in all cases to seek information relating to a recent warning letter issued to Bard by the Food and Drug Administration (FDA), while Bard argued that the letter is largely irrelevant to the pending actions and that it will produce its communications with'the FDA. While acknowledging that there has been some duplication in pretrial motions practice, Bard argues that this is because plaintiffs insist on pressing the same privilege issue unsuccessfully in various courts. Centralization will streamline these discovery disputes, allow the parties to brief plaintiffs’ request for additional discovery once, and result in one ruling on the contested privilege issue. Even if plaintiffs’ counsel are successfully coordinating their discovery efforts and scheduling, re-litigation of the same issues in different courts significantly impacts the parties and the judiciary.

Several of the pending cases have completed discovery and some are near trial. Given the ongoing overlapping discovery disputes, we find that centralization still would promote efficiencies. While it may be that some cases are too advanced to substantially benefit from inclusion in centralized proceedings, the parties have not specifically identified any that should be excluded. The Panel has held that the transferee court is in the best position to identify claims that should be excluded from an MDL. See In re: Nat’l Football League Players’ Concussion Injury Litig., 842 F.Supp.2d 1378, 1379 (J.P.M.L.2012) (“[W]e are persuaded that the transferee judge is in the best position to determine whether those claims are sufficiently related to the NFL claims to remain in centralized proceedings. If the transferee-judge determines after close scrutiny that remand of any claims is appropriate, procedures are available whereby this may be accomplished with a minimum of delay.”).

We are persuaded that the District of Arizona is an appropriate transferee district for this litigation. Defendant BPV— the Bard entity responsible for the design, testing, marketing, labeling, and post-market surveillance of Bard’s IVC filters — is [1377]*1377headquartered in this district and, therefore, documents and witnesses will be found there. The District of Arizona is not burdened by many MDLs and has the capacity and resources to successfully guide this litigation. Judge David G. Campbell, who sits in this district, is an experienced transferee judge who can prudently steer the litigation. Though a related action is not currently pending in the District of Arizona, we have found that is not a bar to centralization in a particular district. See, e.g., In re: New Motor Vehicles Canadian Exp. Antitrust Litig., 269 F.Supp.2d 1372, 1373 (J.P.M.L.2003) (centralizing six actions in the District of Maine though no constituent action was pending in that district).

IT IS THEREFORE ORDERED that the actions listed on Schedule A are transferred to the District of Arizona, and, with the consent of that court, assigned to the Honorable David G. Campbell for coordinated or consolidated pretrial proceedings.

SCHEDULE A

MDL No. 2641 — IN RE: BARD IVC FILTERS PRODUCTS LIABILITY LITIGATION

Central District of California

SIZEMORE v. C.R. BARD, INC, ET AL., C.A. No. 2:15-01945

Middle District of Florida

TILLMAN v. C.R. BARD, INC, ET AL., C.A. No. 3:13-00222 WYATT v. C.R. BARD, INC., ET AL., C.A. No. 6:14-01853

OCASIO, ET AL. v. C.R. BARD, INC., ET AL., C.A. No. 8:13-01962

Middle District of Georgia

MILTON v. C.R. BARD, INC., ET AL., C.A. No. 5:14-00351

Northern District of Illinois

JACKSON, ET AL. v. C.R. BARD, INC, ET AL., C.A. No. 1:14-04080

Eastern District of Michigan

MCCLARTY, ET AL. v. C.R. BARD, INC, ET AL., C.A. No. 4:14-13627

Northern District of Mississippi

MUNSON v. C.R. BARD, INC, ET AL., C.A. No. 3:14-00279

Western District of Missouri

LEUS v. C.R. BARD, INC., ET AL., C.A. No. 4:13-00585

District of Nebraska

KRUSE v. C.R. BARD, INC., ET AL., C.A. No. 8:15-00108

District of New Mexico

ROWE v. C.R. BARD, INC., ET AL., C.A. No. 1:15-00173

Western District of New York

MERRITT v. C.R. BARD, INC., ET AL., C.A. No. 1:14-00917

Northern District of Ohio

ROEDER v. C.R. BARD, INC, C.A. No. 3:15-00858

Eastern District of Pennsylvania

WETZEL v. C.R. BARD, INC., ET AL., C.A. No. 2:14-02729

EBERT v. C.R. BARD, INC., ET AL., C.A. No. 5:12-01253

KEEN v. C.R. BARD, INC., ET AL., C.A. No. 5:13-05361

Middle District of Tennessee

MILLER v. C.R. BARD, INC., ET AL., C.A. No. 3:15-00533

[1378]*1378 Northern District of Texas

BRANCH v. C.R. BARD, INC., ET AL., C.A. No. 3:15-01131

Southern District of Texas

CORONADO v. C.R. BARD, INC., C.A. No. 2:15-00205

CONN, ET AL. v. C.R. BARD, INC., ET AL., C.A. No. 4:14-00298

Eastern District of Wisconsin

ANDERSON v. BARD PERIPHERAL VASCULAR, INC, ET AL., C.A. No. 1:15-00574

HENLEY, ET AL. v. C.R. BARD, INC., ET AL., C.A. No. 2:14-00059

Judge Sarah S. Vance took no part in the decision of this matter,

¹
. The Panel has been informed of sixteen additional related federal actions pending in thirteen district courts. Those actions and ' any other related federal actions are potential tag-along actions. See Panel Rules 1.1(h), 7.1, and 7.2.

Cite This Page — Counsel Stack

Bluebook (online)

122 F. Supp. 3d 1375, 2015 U.S. Dist. LEXIS 107666, 2015 WL 4885543, Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-bard-ivc-filters-products-liability-litigation-jpml-2015.

Opinion

Related

Cite This Page — Counsel Stack